BETA
Your AI-Trained Oncology Knowledge Connection!
July 29th 2025
Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.
July 27th 2025
A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.
July 2nd 2025
The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.
July 1st 2025
A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.
June 24th 2025
AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.
PET-Guided Radiotherapy Successfully Manages Lung and Bone Tumors
Use of PET-guided radiotherapy may enable the opportunity to incorporate biological information into the planning and delivery of radiation.
Treatment Options and AE Considerations in First-Line EGFR+ NSCLC
Experts discuss shifting preferences in EGFR-mutated NSCLC treatments, highlighting new survival data from the FLAURA2 and MARIPOSA trials shared at ELCC 2025.
Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients
Experts discuss innovative treatments for extensive-stage small cell lung cancer, highlighting tarlatamab's potential and management of adverse effects.
Twice-Daily Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC
A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.
THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC
THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.
Six or More Cycles of Chemo Prolong Survival With Atezolizumab in ES-SCLC
The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.
Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLC
Benmelstobart-based regimens provide clinically meaningful PFS benefits as consolidation therapy for unresectable stage III non–small cell lung cancer.
Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC
Neoadjuvant alectinib met the primary end point with a major pathologic response rate of 42% in patients with potentially resectable stage III NSCLC.
3 Things You Should Know About the Multimodal Treatment of SCLC
Here are 3 things you should know about the multimodal treatment of patients with SCLC.
HITOCH After Surgery Appears Safe, May Improve Survival in Mesothelioma
A systematic review shows that patients with mesothelioma who received HITOCH experienced between 13 to 35 months of survival.
Low-Dose CT Screening for Lung Cancer Shows Large-Scale Efficacy
Study data show a small number of individuals with a lung cancer diagnosis within 12 months of a negative baseline screening result.
Chemoimmunotherapy-Enhanced Survival vs Chemotherapy Alone in ES-SCLC
Patients with ES-SCLC who received immunotherapy plus chemotherapy experienced a median OS of 14.9 months vs 11.9 months with chemotherapy alone.
Lung Cancer Screening Adherence Decreases Across Subsequent Testing
Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.
Tislelizumab Significantly Boosts Survival in Lung Cancer Trials
A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.
TTFields Therapy Earns EU Approval in Metastatic Non–Small Cell Lung Cancer
Data from the phase 3 LUNAR trial support the Conformité Européenne Mark for tumor treating fields in metastatic non–small cell lung cancer.
Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC
The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.
3 Things You Should Know About Unresectable NSCLC
In first-line, EGFR-mutated NSCLC, targeted therapies such as osimertinib or amivantamab plus lazertinib are recommended.
Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC
A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.
Mindfulness/Activity Program May Ease Anxiety Over Death from Lung Cancer
End-of-life demands card game and mindfulness-based cancer recovery program use may enhance the quality of life for patients with lung cancer.
Consolidative Thoracic Radiotherapy Improves Survival in ES-SCLC
Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.
Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC
Pooled results from the TRUST-I and TRUST-II trials showed that taletrectinib led to infrequent neurological TEAEs in patients with ROS1-positive NSCLC.
Elucidating Lorlatinib Benefit, ALK TKI Sequencing in ALK-Positive NSCLC
Phase 3 CROWN trial findings suggest that patients with ALK-positive NSCLC may maintain efficacy even after reducing lorlatinib dosing to mitigate AEs.
Surufatinib/Toripalimab Shows Encouraging Activity in NSCLC and SCLC
Surufatinib/toripalimab elicited an ORR of 57.1% in patients with treatment-naïve NSCLC and 15.8% in patients with pretreated SCLC in a phase 2 trial.
Developers Terminate Clinical Program for Ociperlimab in Lung Cancer
A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.
AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC
An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.
Tobacco Control Helps Avert Millions of Lung Cancer Deaths
A stronger commitment to tobacco control at the local, state, and federal levels may further improve progress in preventing smoking-related mortality.
Continuous Second-Line Immunotherapy May Benefit Pretreated Lung Cancer
Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.
AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer
The diagnostic accuracy of radiologists aided by the eyonis LCS AI software was greatly improved compared with when radiologists were unaided.
Cell-Free DNA Assay Achieves High Negative Predicative Value in Lung Cancer
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Blood Testing for Lung Cancer May Address Inadequate Screening Utilization
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.